Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity.

Maikel VerduinLinde HoosemansMaxime VanmechelenMike van HeumenJolanda A F PiepersGaluh AstutiLinda AckermansOlaf E M G SchijnsKim R KampenVivianne C G Tjan-HeijnenBuys A de BarbansonAlida A PostmaDanielle B P EekersMartijn P G BroenJan BeckervordersandforthKaterina StaňkováFrederik de SmetJeremy RichChristopher G HubertGregory GimenezAniruddha ChatterjeeAnn Hoeben Marc A Vooijs

Published in: Neuro-oncology advances (2023)

Overall, these findings demonstrate the robustness of PGOs in retaining the genetic and phenotypic heterogeneity in culture and the application of measuring clinically relevant drug responses. These data show that PGOs have the potential to be further developed into avatars for personalized adaptive treatment selection and actionable drug target discovery and as a platform to study GBM biology.

Keyphrases

single cell
high throughput
small molecule
emergency department
gene expression
genome wide
machine learning
big data
combination therapy
adverse drug
copy number
artificial intelligence